Quarterly ResultAug 5, 2026, 04:15 PM
Sarepta Q2 Revenue $401.3M, GAAP Net Loss $(4.9)M; New CEO Appointed
AI Summary
Sarepta Therapeutics announced its second quarter 2026 financial results, reporting total revenues of $401.3 million, a 34% decrease year-over-year, and a GAAP net loss of $(4.9) million. The company also announced the appointment of Michael Severino, MD, as its new Chief Executive Officer. Sarepta narrowed its full-year 2026 total net product revenue guidance to $1.2-$1.3 billion and reported a strong cash position of $945.0 million. Key pipeline and regulatory updates include progress in DM1, FSHD, and Huntington's disease programs, and FDA acceptance of sNDAs for AMONDYS 45 and VYONDYS 53.
Key Highlights
- Michael Severino, MD, appointed Chief Executive Officer effective July 28, 2026.
- Q2 2026 total revenues were $401.3 million, a 34% decrease from Q2 2025.
- Q2 2026 GAAP net loss was $(4.9) million, compared to $196.9 million net income in Q2 2025.
- Q2 2026 non-GAAP diluted EPS was $0.64, down from $2.02 in Q2 2025.
- FY 2026 total net product revenue guidance narrowed to $1.2-$1.3 billion.
- Ended Q2 2026 with $945.0 million in cash, cash equivalents, and investments.
- FDA accepted sNDAs for AMONDYS 45 and VYONDYS 53 for traditional approval.
- Recorded a $39.0 million litigation contingency charge in Q2 2026.
Price Impact
More from SRPT